依达拉奉对急性脑梗死患者血清NSE、S-100β的影响(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨依达拉奉治疗急性脑梗死的疗效，以及其对血清神经元特异性烯醇化酶(NSE)、S-100β的影响。 方法 68例急性脑梗死患者随机分为观察组(常规治疗+依达拉奉)和对照组(常规治疗)各34例，观察并比较两组的疗效，以及两组治疗前后血清NSE、S-100β的变化。 结果 治疗14 d后，观察组的总有效率明显高于对照组(χ2 =7.852，P < 0.05)。血清NSE和S-100Β水平均较治疗前明显下降(P < 0.05、P < 0.01)，且观察组较对照组降低更明显(P < 0.05)。 结论 依达拉奉治疗急性脑梗死疗效确切，且能明显降低患者血清NSE、S-100β的水平，值得广泛推广和应用。
[关键词] 急性脑梗死；依达拉奉；神经元特异性烯醇化酶(NSE)；S-100β
[中图分类号] R743 [文献标识码] A [文章编号] 1674-4721(2012)07(b)-0067-02
The efficacy of edaravone treatment of acute cerebral infarction and the changes of NSE, S-100β
ZHANG Jianli ZHAO Libo FU Hongjuan
Department of Old Neurology, Heilongjiang Provincial Hospital, Harbin 150036, China
[Abstract] Objective To investigate the efficacy of edaravone treatment of acute cerebral infarction, and to observe the changes of serum neuron-specific enolase(NSE), S-100β. Methods All 68 cases of acute cerebral infarction patients were randomly divided into two groups, the boservation group(conventional treatment of edaravone) and the control group (conventional therapy), each of 34 cases, the efficacy and serum of NSE、S-100β were compared. Results Forteen days after treatment, the total effect rate in the observation group was significantly higher than that of the control group (χ2=7.852, P < 0.05). Serum NSE and S-100β level decreased significantly than that before treatment (P < 0.05, P < 0.01), and the observation group decreased more significantly than control group(P < 0.05). Conclusion The efficacy of edaravone treatment of acute cerebral infarction is good, and it can significantly reduce the serum of NSE, S-100β level, and it is worthy of wide promotion and application.
[Key words] Acute cerebral infarction; Edaravone; Neuron-specific enolase (NSE); S-100β ......
您现在查看是摘要介绍页，详见PDF附件(1892kb)。